Travere reported Filspari net product sales up year-on-year, with contribution from its Tiopronin products. Learn why TVTX ...

Operator: Good morning, and welcome to Travere Therapeutics Second Quarter 2026 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Tuesday reported a loss of $34.8 million in its second quarter. The San Diego-based company said it had a loss of 37 cents per ...

The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable ...

(Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conf ...

Travere Therapeutics stock has delivered a very strong 341.0% return over the past five years, and the current valuation ...

Q2 reframed FILSPARI as a two-indication commercial story, with management emphasizing it was "the first quarter with FILSPARI commercially available across both IgA nephropathy and FSGS" (President, ...

Travere Therapeutics Inc. TVTX shares surged 13.44% to $63.55 in after-hours trading on Tuesday after the biopharmaceutical ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.